These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32068242)

  • 1. Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREATgermany.
    Abraham S; Haufe E; Harder I; Heratizadeh A; Kleinheinz A; Wollenberg A; Weisshaar E; Augustin M; Wiemers F; Zink A; Biedermann T; von Kiedrowski R; Hilgers M; Worm M; Pawlak M; Sticherling M; Fell I; Handrick C; Schäkel K; Staubach P; Asmussen A; Schwarz B; Bell M; Neubert K; Effendy I; Bieber T; Homey B; Gerlach B; Tchitcherina E; Stahl M; Schwichtenberg U; Rossbacher J; Buck P; Mempel M; Beissert S; Werfel T; Weidinger S; Schmitt J;
    Br J Dermatol; 2020 Aug; 183(2):382-384. PubMed ID: 32068242
    [No Abstract]   [Full Text] [Related]  

  • 2. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.
    Bosma AL; Spuls PI; Garcia-Doval I; Naldi L; Prieto-Merino D; Tesch F; Apfelbacher CJ; Arents BWM; Barbarot S; Baselga E; Deleuran M; Eichenfield LF; Gerbens LAA; Irvine AD; Manca A; Mendes-Bastos P; Middelkamp-Hup MA; Roberts A; Seneschal J; Svensson Å; Thyssen JP; Torres T; Vermeulen FM; Vestergaard C; von Kobyletzki LB; Wall D; Weidinger S; Schmitt J; Flohr C
    Br J Dermatol; 2020 Jun; 182(6):1423-1429. PubMed ID: 31444799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on "Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry".
    Seo HM; Oh SU; Park SK; Kim JS
    J Am Acad Dermatol; 2021 Sep; 85(3):e171. PubMed ID: 33667539
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to: "Comment on 'Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry'".
    Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
    J Am Acad Dermatol; 2021 Sep; 85(3):e173-e174. PubMed ID: 33675862
    [No Abstract]   [Full Text] [Related]  

  • 5. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.
    Schmitt J; Abraham S; Trautmann F; Stephan V; Fölster-Holst R; Homey B; Bieber T; Novak N; Sticherling M; Augustin M; Kleinheinz A; Elsner P; Weidinger S; Werfel T
    J Dtsch Dermatol Ges; 2017 Jan; 15(1):49-59. PubMed ID: 27862987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angioedema: A potential complication of dupilumab in atopic dermatitis.
    Fritz AL; Lacy FA; Morrell DS
    Pediatr Dermatol; 2021 Jan; 38(1):237-238. PubMed ID: 33099796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
    Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
    Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atopic dermatitis and depressive symptoms. Results of the German national AD Registry TREATgermany.
    Helmert C; Haufe E; Heinrich L; Siegels D; Abraham S; Heratizadeh A; Harder I; Kleinheinz A; Wollenberg A; Wiemers F; Weisshaar E; Augustin M; von Kiedrowski R; Zink A; Pawlak M; Schäkel K; Wildberger J; Weidinger S; Werfel T; Schmitt J;
    J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):e279-e282. PubMed ID: 34779054
    [No Abstract]   [Full Text] [Related]  

  • 9. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany].
    Haufe E; Abraham S; Heratizadeh A; Harder I; Zink A; Weisshaar E; Kleinheinz A; von Kiedrowski R; Worm M; Bell M; Wollenberg A; Neubert K; Staubach-Renz P; Hilgers M; Bieber T; Fell I; Homey B; Effendy I; Mempel M; Schäkel K; Beissert S; Weidinger S; Werfel T; Schmitt J
    Hautarzt; 2018 Oct; 69(10):815-824. PubMed ID: 30191254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
    Hendricks AJ; Yosipovitch G; Shi VY
    J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
    [No Abstract]   [Full Text] [Related]  

  • 12. Polyenthesitis during treatment with dupilumab for atopic dermatitis.
    Ishibashi M; Honda T; Tabuchi Y; Kabashima K
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e319-e321. PubMed ID: 31991016
    [No Abstract]   [Full Text] [Related]  

  • 13. Dupilumab improved atypical fibrotic skin plaques in atopic dermatitis.
    Nakashima C; Ishida Y; Kaku Y; Epstein EH; Otsuka A; Kabashima K
    Br J Dermatol; 2020 Feb; 182(2):487-488. PubMed ID: 31325158
    [No Abstract]   [Full Text] [Related]  

  • 14. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis.
    Agache I; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong PY; O'Mahony L; Schwarze J; Warner A; Werfel T; Palomares O; Jutel M
    Allergy; 2021 Apr; 76(4):988-1009. PubMed ID: 33538044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of Atopic dermatitis and Hidradenitis Suppurativa successfully treated with Dupilumab.
    Gambardella A; Calabrese G; Di Brizzi EV; Alfano R; Argenziano G
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):e284-e286. PubMed ID: 32034813
    [No Abstract]   [Full Text] [Related]  

  • 16. Exacerbation of psoriasis after initiation of dupilumab in atopic dermatitis patient.
    Dimitrov D; Al Adawi M; Abdelhadi Z; Jafferany M
    Dermatol Ther; 2020 Jul; 33(4):e13572. PubMed ID: 32406135
    [No Abstract]   [Full Text] [Related]  

  • 17. Alopecia areata development in atopic dermatitis patients treated with dupilumab.
    Ständer S; Trense Y; Thaçi D; Ludwig RJ
    J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):e612-e613. PubMed ID: 32311803
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema.
    Treudler R; Delaroque N; Puder M; Simon JC; Szardenings M
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):e30-e32. PubMed ID: 32594596
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of arthralgia during treatment with dupilumab in a patient with atopic dermatitis.
    Arakawa N; Inoue T; Tanji T; Amano H
    J Dermatol; 2021 Aug; 48(8):e397-e398. PubMed ID: 33991014
    [No Abstract]   [Full Text] [Related]  

  • 20. Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?
    Pistone G; Tilotta G; Gurreri R; Castelli E; Curiale S; Bongiorno MR
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):e255-e256. PubMed ID: 31985084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.